Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-18T10:47:49.002Z Has data issue: false hasContentIssue false

The Limits of Disclosure: What Research Subjects Want to Know about Investigator Financial Interests

Published online by Cambridge University Press:  01 January 2021

Extract

Concerns about the influence of financial interests on research have increased, along with research dollars from pharmaceutical and other for-profit companies. Researchers’ financial ties to industry sponsors of research have also increased. Financial interests in biomedical research could influence research design, conduct, or reporting, and could compromise data integrity, participant safety, or both. Investigators’ financial ties with for-profit companies may influence reported scientific results, and may have compromised research participant safety.

Disclosure is one commonly accepted method of managing financial relationships in order to minimize possible threats to scientific objectivity, the safety of research participants, or public trust in the integrity of clinical research. Disclosure is presumed useful to the extent that “it gives those who would be affected, or who are otherwise in a good position to assess the risks, information they need to make their own decision.”

Type
Independent
Copyright
Copyright © American Society of Law, Medicine and Ethics 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bodenheimer, T., “Uneasy Alliance – Clinical Investigators and the Pharmaceutical Industry,” N. Engl. J. Med. 342, no. 20 (2000): 15391544; Warner, T. D. Gluck, J. P., “What do we Really Know about Conflicts of Interest in Biomedical Research?” Psychopharmacology (Berl) 171, no.1 (2003): 36–46; Bekelman, J. E. Li, Y. Gross, C. P., “Scope and Impact of Financial Conflicts of Interest in Biomedical Research,” JAMA 289 (2003): 454–465; Moses, H. Dorsey, E. Matheson, D. Their, S., “Financial Anatomy of Biomedical Research,” JAMA 294 (2005): 1333–1342.CrossRefGoogle Scholar
Boyd, E. A. Bero, L. A., “Assessing Faculty Financial Relationships with Industry: A Case Study,” JAMA 284 (2000): 22092214; Blumenthal, D. et al., “Participation of Life-Science Faculty in Research Relationships with Industry,” N. Engl. J. Med. 335 (1996): 1734–1739; Krimsky, S. et al., “Financial Interests of Authors in Scientific Journals: A Pilot Study of 14 Publications,” Science and Engineering Ethics 2, no. 4 (1996): 395–410.CrossRefGoogle Scholar
See Warner, and Gluck, , supra note 1.Google Scholar
Djulbegovic, B. et al., “The Uncertainty Principle and Industry-Sponsored Research,” Lancet 356, no. 9230 (2000): 635638; Kjaergard, L. L. and Als-Nielsen, B., “Association between Competing Interests and Authors's Conclusions: Epidemiological Study of Randomized Clinical Trials Published in the BMJ,” British Medical Journal 325, no. 7358 (2002): 249; Barnes, D. E. and Bero, L. A., “Why Review Articles on the Health Effects of Passive Smoking Reach Different Conclusions,” JAMA 279 (1998): 1566–1570; Friedman, L. S. Richter, E. D., “Relationship between Conflicts of Interest and Research Results,” Journal of General Internal Medicine 19, no. 1 (2004): 51–56.CrossRefGoogle Scholar
Andrews, L., “Money is Putting People at Risk in Biomedical Research,” Chronicle of Higher Education 46, no. 27 (2000): B1, B45.Google Scholar
Smith, R., “Beyond Conflict of Interest: Transparency is the Key,” British Medical Journal 317 (7154) (1998): 291292; Association of American Medical Colleges (AAMC), Protecting Subjects, Preserving Trust, Promoting Progress II: Principles and Recommendations for Oversight of an Institution's Financial Interests in Human Research (Washington, DC: AAMC, 2002); Resnik, D., Disclosing Conflicts of Interest to Research Subjects: An Ethical and Legal Analysis,” Accountability in Research 11 (2004): 141–159.CrossRefGoogle Scholar
Thomspon, D., “Understanding Financial Conflicts of Interest,” N. Engl. J. Med. 329 (1993): 573576.Google Scholar
Krimsky, S. Rothenberg, L. S., “Financial Interest and its Disclosure in Scientific Publications,” JAMA 280, no. 3 (1998): 225226; Brody, B. Anderson, C. Van McCrary, S. McCullough, L. Morgan, R. Wray, N., “Expanding Disclosure of Conflicts of Interest: The Views of Stakeholders,” IRB Ethics and Human Research 25, no.1 (2003): 1–8.CrossRefGoogle Scholar
McCrary, S. V. Anderson, C. B. Jakovljevic, B. S. Khan, T. McCullough, L. Wray, N. Brody, B., “A National Survey of Policies on Disclosure of Conflicts of Interests in Biomedical Research,” N. Engl. J. Med. 342 (2000): 16211626; DHHS Final Guidance, Financial Relationships and Interest in Research with Human Subjects, 2003, available at <http://www.hhs.gov/ohrp/policy/index.html#topics> (last visited March 24, 2006); Weinfurt, K. Dinan, M. Allsbrook, J. Friedman, J. Hall, M. Schulman, K. Sugarman, J., “Policies of Academic Medical Centers for Disclosing Financial Conflicts of Interest to Potential Research Participants,” Academic Medicine 81, no. 2 (2006): 113–118.CrossRefGoogle Scholar
La Puma, J. Stocking, C. Rhoades, W. Darling, C. Ferner, R. Neuberger, J. VandenBurg, M. Dews, I. Tobias, J., “Financial Ties as Part of Informed Consent to Postmarketing Research: Attitudes of American Doctors and Patients,” British Medical Journal 310 (1995): 16601663; Kim, S. Y. Millard, R. Nisbet, P. Cox, C. Caine, E., “Potential Research Participants' Views Regarding Researcher and Institutional Financial Conflicts of Interest,” Journal of Medical Ethics 30 (2004): 73–79.CrossRefGoogle Scholar
See Kim, S. Y. et al., supra note 10.Google Scholar
Easter Cooperative Oncology Group, ECOG Performance Status, available at <http://www.ecog.org/general/perf_stat.html> (last visited March 24, 2006).+(last+visited+March+24,+2006).>Google Scholar
See Thompson, D., supra note 7, at 576.Google Scholar